The role of smoking in the development and progression of structural damage in axial SpA patients: A systematic review and meta-analysis

Servet Akar¹, Yusuf Cem Kaplan², Sertaç Ecemiş³, Elif Keskin-Arslan², Önyay Gercik¹, Sercan Gücenmez¹, Dilek Solmaz¹

Abstract

Objective: The objective of this study was to determine whether smoking was associated with the cumulative radiographic spinal damage and radiographic progression in patients with ankylosing spondylitis (AS). Thus, we conducted a systematic review and meta-analysis of the available studies to date.

Methods: An electronic search was conducted from inception to June 21, 2016, in EMBASE, the MEDLINE/PubMed Cochrane Central Register of Controlled Trials databases. Cross-sectional and longitudinal cohort studies investigating the association between smoking and cumulative spinal structural damage or radiographic progression were included. The outcome of interest was the presence of syndesmophytes in cross-sectional studies and radiographic progression in longitudinal studies. The quality assessment was done using the Agency for Healthcare Research and Quality checklist. The authors of potentially relevant studies were contacted regarding the unpublished data. Data from eligible cross-sectional studies were extracted and arranged in a 2x2 table. The odds ratios (ORs) and 95% confidence intervals (CIs) for the dichotomous outcome of interest were computed.

Results: The combined data of eight eligible cross-sectional studies for the assessment of association between smoking and cumulative spinal structural damage suggested a significant association (OR, 2.02; 95% CI, 1.51–2.70). No significant heterogeneity was detected between studies (I²=23.0%, p=0.25). The heterogeneity of the longitudinal study data did not permit us to undertake a meta-analysis. Hence, a qualitative review was performed.

Conclusion: The results of our meta-analysis show that smoking is associated with increased cumulative spinal structural damage in patients with AS. Therefore, rheumatologists should encourage patients with AS to quit smoking.

Keywords: Ankylosing spondylitis, syndesmophyte, smoking, meta-analysis

Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by the involvement of axial skeleton. The disease may also affect peripheral joints and entheses. In patients with AS, erosive damage of sacroiliac joints and vertebrae is of limited value. However, new bone formation, which may lead to progressive spinal ankylosis, is the most important long-term outcome of the disease (1). Inflammation and new bone formation almost always start from sacroiliac joints, and approximately 1 in 3 of AS patients have spinal radiographic damage at baseline, whereas more than 10% of patients may develop new syndesmophytes in 2 years of follow-up (2). This progressive spinal ankylosis may lead not only to disease-related signs and symptoms, but also to functional loss and (1, 3, 4).

Molecular mechanisms underlying the new bone formation in patients with AS are not well understood yet. There is some evidence supporting the thesis on the activation of bone morphogenetic protein signal (5) and a decrease in Dickkopf-related protein 1 and sclerostin levels, which are natural inhibitors of the Wnt pathway (6-8). Disease activity may be longitudinally associated with radiographic damage evaluated by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) (2, 9).

Beyond the very well-known association between smoking and cardiovascular diseases, smoking may also have unfavorable effects on inflammatory rheumatic diseases. Smoking is one of the major known environmental risk factors for rheumatoid arthritis (RA), and it increases not only the risk of having RA, but it
also may trigger RA-specific immune reactions to citrullinated proteins in the context of the HLA–DR shared epitope genes (10). Fewer studies evaluated the impact of smoking on AS and axial spondyloarthritis as a whole. A recent study showed that smokers were younger at the onset of inflammatory back pain (11). Smoking was also found to be associated with high disease activity, worse physical functioning, and poor quality of life in patients with AS (11-18). We and some other groups showed that smoking may also be related to the presence of syndesmophytes and spinal radiographic progression (2, 19, 20). Therefore, the aim of this study was to evaluate the relationship between smoking and the cumulative radiographic spinal structural damage, namely the presence of syndesmophytes in cross-sectional studies and their progression in longitudinal studies in patients with AS by using the advantage of the meta-analysis methodology.

Methods

Search strategy

Searches were conducted in PubMed, MEDLINE, Epub & Medline in Process, EMBASE, and Cochrane Central Register of Controlled Trials databases from inception to June 20, 2016, by a professional librarian. Studies published in either English or Turkish were targeted. A manual search was also conducted through the reference list of the previous systematic reviews, and it included studies to identify other possible eligible studies. A detailed presentation of the search process can be found in Appendix 1.

The flow chart was prepared in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (21) and is presented in Figure 1. We adhered to the Meta-Analysis of Observational Studies in Epidemiology guidelines (22) to report our findings.

Inclusion and exclusion criteria

Cross-sectional and longitudinal cohort studies investigating the association between smoking and cumulative spinal structural damage or radiographic progression were included. A study was considered eligible if it met the following criteria: (a) included patients aged >16 years diagnosed with AS according to the modified New York criteria (23); (b) assessed/reported basal radiographic findings and/or radiographic progression or relevant prognostic criteria; (c) reported a minimum of 1-year radiographic follow-up; (d) either events or estimates of risk (odds ratio [OR]) were reported; (e) the data reported were not overlapping with another study (if an overlap between two studies was detected, the most recent one was included, ensuring the methodological quality of the studies were comparable); and (f) the study sample size was >10. The exclusion criteria were case reports and series, animal studies, editorials, and reviews.

Quality assessment

For the quality assessment of the study methodologies, The Agency for Healthcare Research and Quality (ARHQ) checklist (24) was used for cross-sectional studies.

Outcome measures

The outcomes of interest were the presence of syndesmophytes in cross-sectional studies and radiographic progression in longitudinal studies.

Data extraction

Four authors (S.E., S.A., E.K.A., and Y.C.K) independently reviewed the studies. The data were extracted by using a standardized data extraction form and presented in Tables 1 and 2. Any disagreements were resolved by discussion among the authors. We contacted the corresponding authors of potential studies through e-mail regarding additional information.

Meta-analytic methods

The ORs and 95% confidence intervals (CIs) for the dichotomous outcome of interest were computed. The random-effects method was used to combine the outcome data in Comprehensive Meta-analysis Software Version 3.3.070 and RevMan (Review Manager Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Heterogeneity was assessed utilizing the Q- and I-square statistic. An I-square value between 25% and 50% signified low heterogeneity, between 50% and 75% moderate, and >75% high heterogeneity (25). A funnel plot was not utilized to assess the publication bias since it was suggested to have low power for detecting asymmetry with good accuracy if the number of included studies was <10 (26), which was the case with our meta-analysis.

Main Points

- Smoking is related with the cumulative structural damage determined by the presence of syndesmophytes.
- Smoking may also cause an increase in the structural progression.
- Rheumatologists should encourage all AS patients about quitting smoking.

Results

Cross-sectional studies

Our search strategy retrieved 910 relevant results (Figure 1), and 8 cross-sectional studies provided data necessary for the evaluation of effects of smoking on the presence of syndesmophytes (Table 1). Two of the studies were in the abstract form (19, 27). We contacted the authors of relevant studies through e-mail regarding our questions and unpublished data which were provided by 6 authors. The smoking status was analyzed as ever and never smoked. The results of the quality assessment performed by the ARHQ checklist are summarized in Table 1.

In total, 1199 patients from a wide geographical area were included in the analysis. In all the studies, cumulative radiographic damage was reported to be numerically higher in “ever-smoking” patients with AS than patients who never smoked before. The combined data from 8 eligible cross-sectional studies for the assessment of the association between smoking and cumulative spinal structural damage, in other words, the presence of syndesmophytes, suggested a significant association (OR, 2.02; 95% CI, 1.51–2.70). No significant heterogeneity was detected between studies (I²=23.0%, p=0.25) (Figure 2). However, studies included in the meta-analysis may have some differences such as sex and disease duration, which might have an effect on the development of syndesmophytes.

Longitudinal studies

We were unable to perform a meta-analysis for the association between smoking and the progression of radiographic damage in longitudinal studies due to (a) different handling of smoking history in different studies (qualitative vs quantitative data); (b) not presenting or providing the necessary data for the inclusion of meta-analysis; (c) different evaluation procedures in the assessment of radiographic damage (different time intervals or different scoring methods). Therefore, we decided to summarize the results of our systematic literature review.

Haroon et al. (28, 29) published a study evaluating the impact of anti-tumor necrosis factor therapy on radiographic damage in two separate papers. One of these reports is in abstract form, so we summarized the findings of the full article (28). In this multicenter study, authors scored radiographic damage according to the mSASSS in only patients who had two paired radiographs at a minimum 1.5 years interval, and their smoking status assessed a
| Author and year          | Country    | ARHQ checklist Score | Patients and Comparison                                      | Exposure                                                                 | Outcome                                                                 | Results & Notes                                                                 |
|-------------------------|------------|----------------------|--------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Solmaz et al., 2011 (19)| Turkey     | 6/10                 | 114 patients fulfilling the modified New York criteria for AS.| Smoking status was obtained from medical records                         | Vertebral and lateral heel radiographs were evaluated by two independent reviewers for the presence of syndesmophytes and entheseophytes at the insertion of the Achilles tendon or plantar fascia. The numbers of syndesmophyte + and syndesmophyte - patients with regard to their smoking status (current/ever/never) were obtained from unpublished data. | Smoking, male sex, age and BASMI scores are independently associated with structural damage in AS. |
| Tuylu et al., 2014 (54) | Turkey     | 7/9                  | 49 AS patients without syndesmophytes and 45 AS patients with syndesmophytes were included. The Modified New York criteria were fulfilled for AS. | Smoking status (defined as ever/never smoker) was collected as cardiovascular risk factor. | Syndesmophytes on lateral plain radiographs of the cervical and lumbar spine and the anterior sites of the lower and upper portion of each vertebra were randomly and blindly assessed by two rheumatologists. Any disagreements were resolved by both readers together. | Fetuin-A was found as an independent, significant predictor of syndesmophytes. No correlation was detected between presence of syndesmophytes and smoking status. |
| Poddubnyy et al., 2013(20) | Germany  | 7/9                  | 210 patients with axSpA (115 with AS and 95 with non-radiographic axSpA) from the German Spondyloarthritis Inception Cohort (GESPIC) were included. The authors were contacted regarding the data from only the 115 patients with AS. | The patients were assessed with regard to their smoking status and smoking intensity (non-smoker, 10 cigarettes a day and less, 11–20 cigarettes, and more than 20 cigarettes a day) every 6 months during 2 years of follow-up. | The authors used an extended syndesmophytes count including the lateral views of the cervical and lumbar spine, and also antero-posterior views of the lumbar spine. The numbers of syndesmophyte + and syndesmophyte - patients with regard to their smoking status (current/ever/never) were obtained from unpublished data. | The effect of smoking on radiographic spinal progression in axSpA is dependent on smoking intensity and seems to be mediated by increased systemic inflammation in smokers. |
| Joo et al., 2014 (5)    | Republic of Korea | 6/9                 | After exclusion, 365 patients with AS (modified New York criteria) who referred to the Hanyang University Hospital for Rheumatic Disease were included. Patients were classified as severe | Smoking status was obtained from clinical data. | The anterior radiographic changes of the lumbar spine and cervical spine in lateral radiographic view were independently scored according to the mSASSS by two radiologists. Any disagreements were resolved by both | Two SNPs in BMP6 were significantly associated with radiologic severity in patients with AS. |
Table 1. Characteristics of cross-sectional studies (Continued).

| Author and year | Country      | ARHQ checklist Score | Patients and Comparison | Exposure | Outcome | Results & notes |
|-----------------|--------------|----------------------|-------------------------|----------|---------|----------------|
| Klingberg et al., 2014 (55) | Sweden       | 5/9                  | 204 patients fulfilling the modified New York criteria for AS were included. All patients registered the departments of rheumatology at the Sahlgrenska University Hospital and Hospitals of Alingsås and Borås. | The information regard to current and previous smoking, age at onset and disruption of smoking, and average daily cigarette consumption were obtained from patients. Smoking pack-years were subsequently calculated. | Lateral radiographs of the cervical and lumbar spine were scored for chronic AS-related changes using the mSASSS by radiologist. The numbers of syndesmophyte + and syndesmophyte - patients with regard to their smoking status were extracted from Table 1 of study. | A positive correlation was found between smoking pack-years and mSASSS, BASMI, and age. The mSASSS and BASMI scores and age in ever smokers were significantly higher than never smokers. |
| Sakellariou et al., 2015 (56) | Greece       | 9/9                  | TNF treatment naive 106 patients with AS in accordance with modified New York criteria. All patients consulted the outpatient clinics of the Rheumatology Department of 424 General Military Hospital between June 2010 and January 2015. | Smoking status was obtained and quantitative measure of cigarette exposure was determined from measurement of smoking pack years (1 pack year = 20 cigarettes/ day for 1 year). | The severity of radiographic damages on plane radiographs of the pelvis, and lumbar and cervical spine lateral views were scored using the mSASSS at least 3 months apart by a single rheumatologist. All radiographs were also scored by a radiologist to test the agreement between two readers. The numbers of syndesmophyte + and syndesmophyte - patients with regard to their smoking status (current/ever/never) were obtain from unpublished data. | Current smoking and increasing pack years were independently associated with a higher BASDAI score and mSASSS, BASFI and duration of inflammatory back pain. A positive correlation was found between smoking pack-years and mSASSS, BASFI and duration of inflammatory back pain. |
| Rueda-Gotor et al., 2015 (57) | Spain        | 8/9                  | 115 patients fulfilling the modified New York criteria for AS. All patients referred to the Hospital Universitario Marqués de Valdecilla | Smoking status (Non-smokers, current smokers, ex-smokers) was obtained as a part of cardiovascular risk factors. | The numbers of syndesmophyte + and syndesmophyte - patients with regard to their smoking status (current/ever/never) were obtain from unpublished data. | Carotid plaques were significantly frequent in patients with ax-SpA. Plaques were significantly frequent in patients with hip involvement, |
In univariate analysis, smoking was significantly associated with radiographic progression, as defined by a change of ≥1 mSASSS unit/year with an OR of 1.06 (95% CI, 1.02–1.09; p=0.002). Smoking was also a significant predictor for radiographic damage in this study with an OR of 1.09 (95% CI, 1.02–1.17; p=0.01) in the propensity score matching along with baseline mSASSS and anti-TNF usage. The same group had also reported their own experience in 288 patients with AS who had had pairs of radiographs at a minimum interval of 2 years (30) according to the abstract. In this work, authors found that the baseline radiologic damage (OR 22.8) and smoking (OR 2.8) were independent predictors of radiographic progression defined as a ≥2 mSASSS change between two time points. However, from the text, it was not clear how smoking was evaluated and analyzed.

Interestingly, another abstract (31), which also included patients’ data of Haroon et al, reported factors associated with the radiographic progression in 368 patients with AS with two sets of radiographs at least 1.5 years apart from the United States, Canada, and Australia. In this study, smoking was not found to be predictive of radiographic progression defined as more than two mSASSS units in 2 years.

There are several papers (2, 32-36) reporting spinal radiographic damage predictors in the German Spondyloarthropathy Inception Cohort. Among the whole group of axial spondyloarthritis (including both patients with AS and non-radiographic axial spondyloarthritis [nr-axSpA]) patients (2), the authors found in univariate analysis that (a) the presence of syndesmophytes at baseline (OR, 6.29; 95% CI, 2.77–14.26), presence of definite radiographic sacroiliitis (OR, 3.14; 95% CI, 1.28–7.69), elevated C-reactive protein (CRP) level (OR, 2.47; 95% CI, 1.24–4.93), elevated erythrocyte sedimentation rate (ESR) (OR, 4.04; 95% CI, 1.82–8.97), and current smoking (OR, 2.75; 95% CI, 1.25–6.05) were associated with spinal radiographic progression defined as ≥2 mSASSS units after 2 years. The authors also stated that when they analyzed separately all the above-mentioned variables, they still found a significant association in the AS subgroup; however, in nr-axSpA, only the baseline presence of syndesmophytes was significantly associated with spinal radiographic progression. And in the multivariate logistic regression analysis, the authors reported that the baseline radiographic damage, current smoking, elevated ESR, and time-averaged CRP were independent predictors of spinal radiographic damage among the whole group.
The same group also reported the separate analysis of the relationship between smoking and spinal radiographic progression in AS and nr-axSpA subgroups (36). However, this time, smoking was analyzed in three categories: (a) non-smokers, (b) ≤10 cigarettes a day, (c) ≥11 cigarettes a day. Radiographic progression had been defined as (1) worsening of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) by ≥2 units after 2 years and (2) development of a new syndesmophyte or progression of existing syndesmophytes after 2 years. In this analysis, the mSASSS was statistically significantly worse and associated with the intensity of smoking in the AS group (3.12±5.54 in heavy smokers, 0.57±1.70 in moderate smokers, and 0.58±1.78 in non-smokers, p=0.002 for group comparison). Both definitions of spinal radiographic progression in AS were significantly associated with heavy smoking (>10 cigarettes/day). Worsening of the mSASSS score by ≥2 units over 2 years was 12.7% in non-smokers, 25.9% in moderate smokers, and 41.2% in heavy smokers (p<0.05 for heavy smokers vs non-smokers). Likewise, new syndesmophytes or syndesmophyte progression over 2 years was observed at a rate of 14.1% in non-smokers, 14.8% in moderate smokers, and 35.3% in heavy smokers (p<0.05 for heavy smokers vs non-smokers).

Our systematic literature search also revealed several reports regarding the association between smoking and structural progression in AS in the Outcome in AS International Study cohort (37, 38). In total, 184 patients with AS from the Netherlands, Belgium, and France were followed up until 12 years were included in this analysis (38). The authors scored radiographs using the mSASSS and evaluated progression longitudinally in 2-year intervals up to 12 years. According to the smoking status the patients were labeled as smokers and non-smokers. In one report, the authors investigated a direct effect of job type on radiographic progression and indirect effect of job type on the relationship between ASDAS and radiographic progression. In the direct model, researchers did not find any association between smoking and radiographic progression (p=0.22). However, smoking (n=49) lead to a 1.94 (95% CI, 1.00–2.87) unit increase in the 2-year mSASSS score in per one ASDAS unit increase. This relationship was only significant for the whole AS group and men, but not for women, and it was replicated in their sensitivity analysis.

Table 2. The data regarding smoking status and syndesmophyte which were extracted from cross-sectional studies.

| Country of origin | Age, years (mean±SD) | Male (%) | B27 + (%) | Disease duration, years (mean±SD) | Smokersa (%) | Syndesmophyte in ever smokersa (%) | Syndesmophyte in never smokersa (%) |
|-------------------|----------------------|----------|-----------|---------------------------------|-------------|-----------------------------------|-----------------------------------|
| Solmaz et al. (19), 2011 (n=114) | Turkish | 40.7±11.4 | 67.5 | NA | 6.7±7.9 | 71.7 | 61 | 39.1 |
| Poddubnyy et al. (20), 2013 (n=115) | German | 37.1±10.6 | 51 | 79 | 4.2±2.7 | 38 | 52.2 | 35.2 |
| Tuyu et al. (54), 2014 (n=94) | Turkish | NA | 69.1 | NA | NA | 75.5 | 50.7 | 39.1 |
| Joo et al. (5), 2014 (n=365) | Korean | 37.0±8.6 | 93.2 | 97.1 | 14.1±6.8 | 55 | 56.7 | 49.3 |
| Klingberg et al. (55), 2014 (n=197) | Swedish | 49(17-78)* | 57 | 87 | 12(1-47)* | 46 | 63.3 | 31.7 |
| Sakellariou et al. (56), 2015 (n=106) | Greek | 41.5±12.7 | 94.3 | 65.8 | 15.6±11.2 | 79.2 | 76.1 | 63.6 |
| Rueda-Gotor et al. (57), 2015 (n=115) | Spanish | 46.2±11.9 | 59 | 72.4 | NA | 52.3 | 50.7 | 32 |
| Betancur et al. (27) 2015 (n=93) | Argentinean | 45* | 74.2 | NA | 18.5* | 53.7 | 62 | 48.8 |
| Total (n=1199) | NA | 59 | 42.3 |

NA: Not available.
*These data were presented as median and range values.
+The percentages of smokers, syndesmophyte in ever smokers, syndesmophyte in never smokers were extracted from published and unpublished data.

Figure 1. PRISMA flow diagram of cross-sectional studies.
Another cohort (Groningen Leeuwarden AS [GLAS] cohort) from the Netherlands included consecutive 176 patients with AS who were started on anti-TNF therapy (39), and 50 had reached 6 years of follow-up. Radiographs were scored by using mSASSS, and spinal radiographic progression was analyzed longitudinally by the generalized estimating equations analytic technic. Interestingly, the smoking status was included in the analysis as the duration of smoking. Although it was found to be associated with the presence of syndesmophytes at baseline ($p=0.02$), during the follow-up, there was no relationship between the radiographic progression and smoking among patients with AS treated with anti-TNF ($p=0.117$).

Another study from Alberta, Canada, that evaluated the effects of anti-TNF therapy on radiographic progression in 384 patients with AS (40) used mSASSS for the analysis. In this work, the authors reported that smoking was not associated with radiographic progression. However, it is not clear how they handled the smoking status.

**Discussion**

The results of the present meta-analysis revealed that smoking was related to cumulative structural damage in AS because we showed that the patients who ever smoked had significantly more syndesmophytes than those who had never smoked. In addition, smoking might be one of the risk factors for spinal structural progression in patients with AS. The underlying mechanism behind the association of smoking and new bone formation has not been clearly understood yet. Previous studies suggested that smoking might have some effects on both cellular and humoral components of the immune system: (a) smoking may cause a change in the generation of reactive oxygen species (10, 41); (b) leukocytosis and decreased leukocyte function was found in chronic smoke exposure (41-44); (c) CRP serum levels, (C-C motif) ligand CCL 17/thymus, activation regulated chemokine (CCL17/TARC), and CCL11/EOTAXIN were found to be increased, and some of the cytokines and soluble receptors (IL-15, IL-1Ra, IL-1β, IL-16, SCF, sIL-6R and sVEGFR3) were reported to be decreased in current smokers in comparison to individuals who have never smoked before (45). In addition, there were similar levels of CRP, chemokines (CCL17/TARC, CCL11/EOTAXIN), and some of the cytokines (IL-15, IL-1β, IL-1Ra) found in former smokers and individuals who have never smoked before. These findings might indicate various deviations in the immune/inflammatory response, such as chemotaxis of T-cells, eosinophils, and other cells; pro- and anti-inflammatory processes; as well as markers involved in cell development/differentiation, cell growth and activation, angiogenesis, and hematopoiesis (45).

The main limitation of this systematic review was that we were not able to perform a meta-analysis by using longitudinal data regarding the impact of smoking on the structural progression in patients with AS. In addition to a different handling of smoking history in available studies, the way of quantification of structural progression has restricted us in this regard. However, it may not be possible to fully extract the effect of smoking on structural damage from other confounding factors in cross-sectional studies. Conventional X-rays of the spine are still considered the gold standard for the assessment of the presence and the progression of structural changes (46-48). However, the scoring of radiographs in AS is somehow difficult (49). The mSASSS has been considered to be the best scoring method for the evaluation of structural changes in the spine of patients with AS (50), because it was reported that mSASSS was sensitive to change in determination and quantification of radiographic progression over a 2-year interval (46, 51). Since radiographic progression is a slow process, detection of real progression might be jeopardized by the measurement error in the sequential scoring in intervals shorter than 2 years. However, the assessment of progression in the conditions such as (a) paired reading of films in random order and (b) cutoff based on smallest detectable differences (SDD) for inter-observer data might also decrease the reliability of method for the determination of progression in some patients with AS (49, 52)0-36 each. Therefore, simultaneously paired reading of graphs and smallest detectable change instead of SDD was recommended (52).

In our study, we used the presence of syndesmophytes as a surrogate marker of cumulative structural damage in cross-sectional evaluation of patients with AS. Previously, we revealed that the kappa agreement among readers for the presence of syndesmophytes were markedly better than the squaring, erosion, and sclerosis and highest for ankylosis (53). It was also suggested that the calculation of proportion of patients with AS with definite radiographic progression defined as the presence of syndesmophytes or ankylosis might be regarded as the gold standard in the evaluation of radiographic change in AS, since the presence of definite radiographic damage was shown to be more predictive of radiographic progression (46).

In conclusion, considering a very high frequency of smoking among patients with AS and the available evidence about the negative impact of smoking on the structural damage, it is clear that we should strongly encourage our patients with AS to quit smoking.

You can reach the appendix of this article at eurjrheumatol.org.

**Ethics Committee Approval:** N/A.

**Informed Consent:** N/A.

**Peer-review:** Externally peer-reviewed.

| Study or Subgroup | Exposed Events Total | Control Events Total | Weight | Odds Ratio M-H, Random, 95% CI Year |
|-------------------|----------------------|----------------------|--------|-----------------------------------|
| Tuyu et al.       | 36                   | 71                   | 9      | 23                                |
| Solmaz et al.     | 50                   | 82                   | 11     | 32                                |
| Podolubny et al.  | 23                   | 44                   | 25     | 71                                |
| Klingberg et al.  | 59                   | 93                   | 33     | 104                               |
| Joo et al.        | 114                  | 201                  | 81     | 164                               |
| Sakellariou et al.| 64                   | 84                   | 14     | 22                                |
| Rueda-Gotier et al.| 33                   | 65                   | 16     | 50                                |
| Belancour et al.  | 31                   | 50                   | 21     | 43                                |
| **Total (95% CI)** | **690**              | **509**              | **100.0%** | **2.02 [1.51, 2.70]** |

| Heterogeneity: Tau² = 0.04; Chi² = 9.09, df = 7 (P = 0.25); I² = 23% | Test for overall effect: Z = 4.77 (P < 0.00001) |
Author Contributions: Concept - S.A., Y.C.K., S.E., E.K.A., O.G., S.G., D.S.; Design - S.A., Y.C.K., S.E., E.K.A., O.G., S.G., D.S.; Supervision - S.A., Y.C.K., S.E., E.K.A., O.G., S.G., D.S.; Literature Search - S.A., Y.C.K., S.E., E.K.A., O.G., S.G., D.S.; Writing Manuscript - S.A., Y.C.K., S.E., E.K.A., O.G., S.G., D.S.

Acknowledgements: We would like to express our sincere thanks to Dr. Dilek Solmaz, Dr Denis Poddubnyy, Dr Eva Klingberg, Dr Javier Rueda-Gotor, Dr Grigoriois T. Sakellariou and Dr. Graciela Betancur for answering us the details of their studies and providing unpublished data.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References
1. Lories RJ, Haroon N. Bone formation in axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014; 28: 765-77. [CrossRef]
2. Poddubnyy D, Haeibel H, Listing J, Merker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64: 1388-98. [CrossRef]
3. Machado P, Landewe R, Braun J, Hermann KGA, Baker D, Van Der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69: 1465-70. [CrossRef]
4. Healey EL, Haywood KL, Jordan KP, Garratt A, Packham JC. Impact of ankylosing spondylitis on work in patients across the UK. Scand J Rheumatol 2011; 40: 34-40. [CrossRef]
5. Joo YB, Bang SY, Kim T-H, Shim S-C, Lee S, Joo K Bin, et al. Bone Morphogenetic Protein 6 Polymorphisms Are Associated with Radiographic Progression in Ankylosing Spondylitis. PLoS One 2014; 9: e104966. [CrossRef]
6. Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012; 32: 2523-7. [CrossRef]
7. Appel H, Ruiz-Helland G, Listing J, Zwerina J, Hermann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60: 3257-62. [CrossRef]
8. Olmez D, Uslu S, Kozaçi D, Karaca N, Rubulb H, Tarhan EF, et al. Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: Peristin may be associated with the Wnt pathway. Int J Rheum Dis 2018; 21: 502-9. [CrossRef]
9. Ramiro S, van der Heijide D, van Tuberagen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2013; 72: 1455-61. [CrossRef]
10. Klarskov L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46. [CrossRef]
11. Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougdas M. Smokers in early axial spondyloarthrities have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: Results from the DESIR cohort. Ann Rheum Dis 2017; 79: 165-71. [CrossRef]
12. Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005; 25: 357-60. [CrossRef]
13. Doran MF, Brophy S, MacKay K, Taylor G, Calin A. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003; 30: 316-20. [CrossRef]
14. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996; 25: 138-42. [CrossRef]
15. Ward MM, Weisman MH, Davis JC, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005; 53: 710-7. [CrossRef]
16. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002; 29: 1420-5. [CrossRef]
17. Bodur H, Ataman S, Rezvani A, Bugdayci DS, Cevik R, Britane M, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011; 20: 543-9. [CrossRef]
18. Ward MM, Hendrey MR, Malley JD, Leach TJ, Davis JC, Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Care Res 2009; 61: 859-66. [CrossRef]
19. Solmaz D, Akar S, Sari I, Soyosal O, Gerdan V, Oen F, et al. Smoking is associated with syndesmophyte development in ankylosing spondylitis (abstract). Arthritis Rheum 2011; 63: P550. [CrossRef]
20. Poddubnyy D, Haeibel H, Listing J, Merker-Hermann E, Zeidler H, Braun J, et al. Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2011; 63: 1480-2. [CrossRef]
21. Moher D, Liberat A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. [CrossRef]
22. Stroop DF, Berlin JA, Morton SC, Olkin I, Williams GD, Remmes D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. [CrossRef]
23. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8. [CrossRef]
Akar et al. Role of smoking in ankylosing spondylitis

37. Ramiro S, van Tubergen A, Landewé R, Stolwijk C, Dougdas M, van den Bosch F, et al. Disease activity in male smokers has a >10-fold amplified effect on radiographic damage in comparison with female non-smokers in ankylosing spondylitis. Ann Rheum Dis 2014; 73(Suppl 2). [CrossRef]

38. Ramiro S, Landewé R, van Tubergen A, Boonen A, Stolwijk C, Dougdas M, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 2015; 14:e000153.

39. Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-alpha blocking therapy: A prospective longitudinal observational cohort study. PLoS One 2015; 16:e0122693. [CrossRef]

40. Maksymowycz WP, Zheng Y, Wichuk S, Chio-wchanwisawakit P, Lambert RG. The effect of TNF inhibition on radiographic progression in ankylosing spondylitis: An observational cohort study of 384 patients. Ann Rheum Dis 2015; 74(Suppl 2): 975. [CrossRef]

41. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and Rheumatoid Arthritis. Int J Mol Sci 2014; 15: 22279-95. [CrossRef]

42. Kawada T. Smoking-induced leukocytosis can persist after cessation of smoking. Arch Med Res 2004; 35: 246-50. [CrossRef]

43. Johnson JD, Houchens DP, Kluwe WM, Craig DK, Fisher GL. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: A review. Crit Rev Toxicol 1990; 20: 369-95. [CrossRef]

44. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 2014; 106: pii: dju294.

45. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: Defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66: 910-5. [CrossRef]

46. Braun J, Van Der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002; 16: 573-604. [CrossRef]

47. Heuft-Dorenbosch L, Landewé R, Weijers R, Wanders A, Houben H, Van Der Linden S, et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006; 65: 804-8. [CrossRef]

48. Spoorenberg A, de Vlam K, van der Linden S, Dougdas M, Mielants H, van de Tempel H, et al. Radiological scoring methods in ankylosing spondylitis: Reliability and change over 1 and 2 years. J Rheumatol 2004; 31: 125-32.

49. Wanders AJB, Landewé RBM, Spoorenberg A, Dougdas M, Van Der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004; 50: 2622-32. [CrossRef]

50. Boers M, Brooks P, Strand CV, et al. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25: 198-9.

51. Bruynesteyn K, Boers M, Kostense P, Van Der Linden S, Van Der Heijde D. Deciding on progression of joint damage in paired films of individual patients: Smallest detectable difference or change. Ann Rheum Dis 2005; 64: 179-82. [CrossRef]

52. Aydin SZ, Gunal EK, Kurum E, Akar S, Mungan HE, Alibaz-Oner F, et al. Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis. Rheumatol (United Kingdom) 2017; 56: 2162-9. [CrossRef]

53. Tuylu T, Sari I, Solmaz D, Kozaci DL, Akar S, Gunay N, et al. Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo) 2014; 69: 688-93. [CrossRef]

54. Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014; 41: 1349-56. [CrossRef]

55. Sakellaricou GT, Anastasilakis AD, Kenanidis E, Potoupinis M, Tsiridis E, Savvidis M, et al. The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis. Rheumatol Int 2017; 36: 2162-9. [CrossRef]

56. Rueda-Gotor J, Corrales A, Blanco R, Fuentevilla P, Portilla V, Expósito R, et al. Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques. Clin Exp Rheumatol 2015; 33: 315-20.
Appendix 1. Detailed presentation of the search process

1. PubMed Search

Database: PubMed
Date searched: June 21, 2016
Topic: Is smoking associated with radiographic damage in axial spondylarthritis?

Search #1 39096
(((spondylarth* OR spondyloarth* OR spondyl-arth* OR spondylo-arth*)) OR (((anky* AND (spondy* OR spin* OR verteb* OR axial* OR sacro* OR lumbar* OR pelvi*)))) OR ((((spondy* AND (spondy* OR spin* OR verteb* OR axial* OR sacro* OR lumbar* OR pelvi*))))) OR (((rheumatoid AND spondy*))))) OR (bechterew* OR marie-strumpell* OR axial SpA OR AxSpA OR ASAS OR ASDAS OR SASSS OR mSASSS OR m-SASSS OR BASRI OR BASDAI OR BASFI OR BASMI OR BAS-G OR ASQoL))

Search #2 313850
(tobacco* OR smoking OR smoker OR smokers OR cigar* OR nicotine*)

Search #3 2873900
(publisher[sb] OR inprocess[sb] OR pubmednotmedline[sb] OR pubstatusaheadofprint)

Search #4
#1 AND #2 AND #3 55

Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties of any kind, expressed, implied, or statutory regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.
2. Embase Search

Database: Embase 1974 to 2016 June 20
Date searched: June 21, 2016
Topic: Is smoking associated with radiographic damage in axial spondylarthropathy?

| #   | Search                                                                 | Results | Type    |
|-----|------------------------------------------------------------------------|---------|---------|
| 1   | spondylarthritis/                                                     | 3920    | Advanced|
| 2   | spondylarthritis/                                                     | 3920    | Advanced|
| 3   | spondyloarthropathy/                                                  | 4476    | Advanced|
| 4   | bath ankylosing spondylitis disease activity index/                   | 1936    | Advanced|
| 5   | bath ankylosing spondylitis functional index/                         | 1127    | Advanced|
| 6   | bath ankylosing spondylitis metrology index/                          | 96      | Advanced|
| 7   | spondylarth*.mp,kw.                                                  | 12561   | Advanced|
| 8   | spondyl?-arth*.mp,kw.                                                | 131     | Advanced|
| 9   | (anky* adj2 spondyl*).mp,kw.                                          | 26014   | Advanced|
| 10  | (anky* adj2 spin*).mp,kw.                                             | 627     | Advanced|
| 11  | (anky* adj2 verteb*).mp,kw.                                           | 161     | Advanced|
| 12  | (anky* adj2 axial*).mp,kw.                                            | 77      | Advanced|
| 13  | (anky* adj2 sacro*).mp,kw.                                            | 144     | Advanced|
| 14  | (anky* adj2 lumbar*).mp,kw.                                           | 15      | Advanced|
| 15  | (anky* adj2 pelvi*).mp,kw.                                            | 19      | Advanced|
| 16  | (spondy* adj2 spin*).mp,kw.                                           | 1046    | Advanced|
| 17  | (spondy* adj2 verteb*).mp,kw.                                         | 357     | Advanced|
| 18  | (spondy* adj2 axial*).mp,kw.                                          | 1590    | Advanced|
| 19  | (spondy* adj2 sacro*).mp,kw.                                          | 278     | Advanced|
| 20  | (spondy* adj2 lumbar*).mp,kw.                                         | 1568    | Advanced|
| 21  | (spondy* adj2 pelvi*).mp,kw.                                          | 57      | Advanced|
| 22  | (rheumatoid adj2 spondyl*).mp,kw.                                     | 644     | Advanced|
| 23  | bechterew*.mp,kw.                                                     | 846     | Advanced|
| 24  | marie-strumpell*.mp,kw.                                              | 39      | Advanced|
| 25  | axial SpA.mp,kw.                                                      | 790     | Advanced|
| 26  | AxSpA.mp,kw.                                                          | 673     | Advanced|
| 27  | ASAS.mp,kw.                                                           | 1792    | Advanced|
| 28  | ASDAS.mp,kw.                                                          | 704     | Advanced|
| 29  | SASSS.mp,kw.                                                          | 46      | Advanced|
| 30  | mSASSS.mp,kw.                                                         | 390     | Advanced|
| 31  | m-SASSS.mp,kw.                                                        | 13      | Advanced|
| 32  | BASRI.mp,kw.                                                          | 201     | Advanced|
| 33  | BASDAI.mp,kw.                                                         | 2592    | Advanced|
| 34  | BASFI.mp,kw.                                                          | 1604    | Advanced|
| 35  | BASMI.mp,kw.                                                          | 626     | Advanced|
| 36  | BAS-G.mp,kw.                                                          | 115     | Advanced|
| 37  | ASQoL.mp,kw.                                                          | 286     | Advanced|
| 38  | or/1-37                                                              | 35962   | Advanced|
| 39  | exp "smoking and smoking related phenomena"/                          | 264558  | Advanced|
| 40  | exp "tobacco use"/                                                    | 253119  | Advanced|
| 41  | tobacco consumption/                                                  | 946     | Advanced|
| 42  | exp smoking/                                                          | 250395  | Advanced|
| 43  | cigarette smoke/                                                      | 9828    | Advanced|
| 44  | tobacco smoke/                                                        | 10963   | Advanced|
| 45  | tobacco dependence/                                                   | 15827   | Advanced|
| 46  | smoking cessation/                                                    | 44790   | Advanced|
| 47  | tobacco/                                                               | 39069   | Advanced|
| 48  | nicotine/                                                             | 40537   | Advanced|
| 49  | tobacco*.mp,kw.                                                       | 119174  | Advanced|
| 50  | smoking.mp,kw.                                                        | 359480  | Advanced|
| 51  | smoke??mp,kw.                                                         | 148847  | Advanced|
| 52  | cigar*mp,kw.                                                          | 98380   | Advanced|
| 53  | nicotine*mp,kw.                                                       | 56621   | Advanced|
| 54  | or/39-53                                                             | 465845  | Advanced|
| 55  | 38 and 54                                                             | 737     | Advanced|
| 56  | (exp animals/ or exp animal experimentation/ or nonhuman/) not         | 5933265 | Advanced|
|     | ((exp animals/ or exp animal experimentation/ or nonhuman/) and exp human/) |         |         |
| 57  | 55 not 56                                                             | 736     | Advanced|
| 58  | limit 57 to (english or turkish)                                       | 708     | Advanced|

Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties of any kind, expressed, implied, or statutory regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.
3. Epub and Medline Search

Database: Epub Ahead of Print and In-Process & Other Non-Indexed Citations Ovid MEDLINE(R) June 20, 2016
Date searched: June 21, 2016
Topic: Is smoking associated with radiographic damage in axial spondyloarthitis?

| # | Searches                                                                 | Results | Type |
|---|--------------------------------------------------------------------------|---------|------|
| 1 | spondyl?arth*.mp,kw.                                                    | 638     | Advanced |
| 2 | spondyl?-arth*.mp,kw.                                                   | 5       | Advanced |
| 3 | (anky* adj2 spondy*)mp,kw.                                              | 1034    | Advanced |
| 4 | (anky* adj2 spin*)mp,kw.                                                | 55      | Advanced |
| 5 | (anky* adj2 verteb*)mp,kw.                                              | 10      | Advanced |
| 6 | (anky* adj2 axial*)mp,kw.                                               | 17      | Advanced |
| 7 | (anky* adj2 sacro*)mp,kw.                                               | 13      | Advanced |
| 8 | (anky* adj2 lumbar*)mp,kw.                                              | 3       | Advanced |
| 9 | (anky* adj2 pelvi*)mp,kw.                                               | 2       | Advanced |
| 10| (spondy* adj2 spin*)mp,kw.                                              | 176     | Advanced |
| 11| (spondy* adj2 verteb*)mp,kw.                                            | 44      | Advanced |
| 12| (spondy* adj2 axial*)mp,kw.                                             | 153     | Advanced |
| 13| (spondy* adj2 sacro*)mp,kw.                                             | 28      | Advanced |
| 14| (spondy* adj2 lumbar*)mp,kw.                                            | 206     | Advanced |
| 15| (spondy* adj2 pelvi*)mp,kw.                                             | 3       | Advanced |
| 16| (rheumatoid adj2 spondy*)mp,kw.                                         | 35      | Advanced |
| 17| bechterew*.mp,kw.                                                       | 6       | Advanced |
| 18| marie-strumpell*.mp,kw.                                                 | 1       | Advanced |
| 19| axial SpA.mp,kw.                                                        | 41      | Advanced |
| 20| AxSpA.mp,kw.                                                            | 62      | Advanced |
| 21| ASAS.mp,kw.                                                             | 104     | Advanced |
| 22| ASDAS.mp,kw.                                                            | 35      | Advanced |
| 23| SASSS.mp,kw.                                                            | 3       | Advanced |
| 24| mSASSS.mp,kw.                                                           | 20      | Advanced |
| 25| m-SASSS.mp,kw.                                                          | 0       | Advanced |
| 26| BASRI.mp,kw.                                                            | 8       | Advanced |
| 27| BASDAI.mp,kw.                                                           | 117     | Advanced |
| 28| BASFI.mp,kw.                                                            | 73      | Advanced |
| 29| BASMI.mp,kw.                                                            | 28      | Advanced |
| 30| BAS-G.mp,kw.                                                            | 7       | Advanced |
| 31| ASQoL.mp,kw.                                                            | 18      | Advanced |
| 32| or/1-31                                                                 | 1827    | Advanced |
| 33| smoking.mp,kw.                                                          | 17509   | Advanced |
| 34| smoke??mp,kw.                                                           | 10131   | Advanced |
| 35| cigar*.mp,kw.                                                           | 5190    | Advanced |
| 36| nicotine*.mp,kw.                                                        | 2876    | Advanced |
| 37| tobacco*.mp,kw.                                                         | 9966    | Advanced |
| 38| or/33-37                                                                | 29215   | Advanced |
| 39| 32 and 38                                                               | 35      | Advanced |

Results of database searches are subject to limitations of the database(s) searched. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the search results. While the staff of HealthSearch makes every effort to ensure that the information gathered is accurate and up-to-date, HealthSearch disclaims any warranties of any kind, expressed, implied, or statutory regarding the accuracy or completeness of the information or its fitness for a particular purpose. HealthSearch provides information from public sources both in electronic and print formats and does not guarantee its accuracy, completeness or reliability. The information provided is only for the use of the Client and no liability is accepted by HealthSearch to third parties.